Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 36

1.

TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.

Dowling DJ, van Haren SD, Scheid A, Bergelson I, Kim D, Mancuso CJ, Foppen W, Ozonoff A, Fresh L, Theriot TB, Lackner AA, Fichorova RN, Smirnov D, Vasilakos JP, Beaurline JM, Tomai MA, Midkiff CC, Alvarez X, Blanchard JL, Gilbert MH, Aye PP, Levy O.

JCI Insight. 2017 Mar 23;2(6):e91020. doi: 10.1172/jci.insight.91020.

2.

Toll-like Receptor 4 Ligands Down-regulate Fcγ Receptor IIb (FcγRIIb) via MARCH3 Protein-mediated Ubiquitination.

Fatehchand K, Ren L, Elavazhagan S, Fang H, Mo X, Vasilakos JP, Dietsch GN, Hershberg RM, Tridandapani S, Butchar JP.

J Biol Chem. 2016 Feb 19;291(8):3895-904. doi: 10.1074/jbc.M115.701151. Epub 2015 Dec 22.

3.

Granzyme B expression is enhanced in human monocytes by TLR8 agonists and contributes to antibody-dependent cellular cytotoxicity.

Elavazhagan S, Fatehchand K, Santhanam V, Fang H, Ren L, Gautam S, Reader B, Mo X, Cheney C, Briercheck E, Vasilakos JP, Dietsch GN, Hershberg RM, Caligiuri M, Byrd JC, Butchar JP, Tridandapani S.

J Immunol. 2015 Mar 15;194(6):2786-95. doi: 10.4049/jimmunol.1402316. Epub 2015 Feb 9.

4.

Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with high-risk melanoma.

Sabado RL, Pavlick A, Gnjatic S, Cruz CM, Vengco I, Hasan F, Spadaccia M, Darvishian F, Chiriboga L, Holman RM, Escalon J, Muren C, Escano C, Yepes E, Sharpe D, Vasilakos JP, Rolnitzsky L, Goldberg J, Mandeli J, Adams S, Jungbluth A, Pan L, Venhaus R, Ott PA, Bhardwaj N.

Cancer Immunol Res. 2015 Mar;3(3):278-287. doi: 10.1158/2326-6066.CIR-14-0202. Epub 2015 Jan 29.

5.

Effective innate and adaptive antimelanoma immunity through localized TLR7/8 activation.

Singh M, Khong H, Dai Z, Huang XF, Wargo JA, Cooper ZA, Vasilakos JP, Hwu P, Overwijk WW.

J Immunol. 2014 Nov 1;193(9):4722-31. doi: 10.4049/jimmunol.1401160. Epub 2014 Sep 24.

6.

Combination therapy targeting toll like receptors 7, 8 and 9 eliminates large established tumors.

Zhao BG, Vasilakos JP, Tross D, Smirnov D, Klinman DM.

J Immunother Cancer. 2014 May 13;2:12. doi: 10.1186/2051-1426-2-12. eCollection 2014.

7.

Differential regulation of oxidative burst by distinct β-glucan-binding receptors and signaling pathways in human peripheral blood mononuclear cells.

Bose N, Wurst LR, Chan AS, Dudney CM, LeRoux ML, Danielson ME, Will PM, Nodland SE, Patchen ML, Dalle Lucca JJ, Lebeda FJ, Vasilakos JP.

Glycobiology. 2014 Apr;24(4):379-91. doi: 10.1093/glycob/cwu005. Epub 2014 Jan 16.

PMID:
24440830
8.

Binding of Soluble Yeast β-Glucan to Human Neutrophils and Monocytes is Complement-Dependent.

Bose N, Chan AS, Guerrero F, Maristany CM, Qiu X, Walsh RM, Ertelt KE, Jonas AB, Gorden KB, Dudney CM, Wurst LR, Danielson ME, Elmasry N, Magee AS, Patchen ML, Vasilakos JP.

Front Immunol. 2013 Aug 12;4:230. doi: 10.3389/fimmu.2013.00230. eCollection 2013.

9.

The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.

Vasilakos JP, Tomai MA.

Expert Rev Vaccines. 2013 Jul;12(7):809-19. doi: 10.1586/14760584.2013.811208. Review.

PMID:
23885825
10.

Activation of the innate immune receptor Dectin-1 upon formation of a 'phagocytic synapse'.

Goodridge HS, Reyes CN, Becker CA, Katsumoto TR, Ma J, Wolf AJ, Bose N, Chan AS, Magee AS, Danielson ME, Weiss A, Vasilakos JP, Underhill DM.

Nature. 2011 Apr 28;472(7344):471-5. doi: 10.1038/nature10071.

11.

TLR-7 and -8 agonists as vaccine adjuvants.

Tomai MA, Vasilakos JP.

Expert Rev Vaccines. 2011 Apr;10(4):405-7. doi: 10.1586/erv.11.26. No abstract available.

PMID:
21506636
12.

Comparison of human B cell activation by TLR7 and TLR9 agonists.

Hanten JA, Vasilakos JP, Riter CL, Neys L, Lipson KE, Alkan SS, Birmachu W.

BMC Immunol. 2008 Jul 24;9:39. doi: 10.1186/1471-2172-9-39.

13.

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

Inglefield JR, Dumitru CD, Alkan SS, Gibson SJ, Lipson KE, Tomai MA, Larson CJ, Vasilakos JP.

J Interferon Cytokine Res. 2008 Apr;28(4):253-63. doi: 10.1089/jir.2007.0097.

PMID:
18439103
14.

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

Dudek AZ, Yunis C, Harrison LI, Kumar S, Hawkinson R, Cooley S, Vasilakos JP, Gorski KS, Miller JS.

Clin Cancer Res. 2007 Dec 1;13(23):7119-25.

15.

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists.

Birmachu W, Gleason RM, Bulbulian BJ, Riter CL, Vasilakos JP, Lipson KE, Nikolsky Y.

BMC Immunol. 2007 Oct 12;8:26.

16.

Resiquimod and other immune response modifiers as vaccine adjuvants.

Tomai MA, Miller RL, Lipson KE, Kieper WC, Zarraga IE, Vasilakos JP.

Expert Rev Vaccines. 2007 Oct;6(5):835-47. Review.

PMID:
17931162
17.

Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells.

Ramakrishna V, Vasilakos JP, Tario JD Jr, Berger MA, Wallace PK, Keler T.

J Transl Med. 2007 Jan 25;5:5.

18.

Oligodeoxynucleotides differentially modulate activation of TLR7 and TLR8 by imidazoquinolines.

Gorden KK, Qiu X, Battiste JJ, Wightman PP, Vasilakos JP, Alkan SS.

J Immunol. 2006 Dec 1;177(11):8164-70.

19.

Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.

Gorden KK, Qiu XX, Binsfeld CC, Vasilakos JP, Alkan SS.

J Immunol. 2006 Nov 15;177(10):6584-7.

20.

Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.

Hammerbeck DM, Burleson GR, Schuller CJ, Vasilakos JP, Tomai M, Egging E, Cochran FR, Woulfe S, Miller RL.

Antiviral Res. 2007 Jan;73(1):1-11. Epub 2006 Aug 18.

PMID:
16959331
21.

Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.

Gorski KS, Waller EL, Bjornton-Severson J, Hanten JA, Riter CL, Kieper WC, Gorden KB, Miller JS, Vasilakos JP, Tomai MA, Alkan SS.

Int Immunol. 2006 Jul;18(7):1115-26. Epub 2006 May 25.

PMID:
16728430
22.

Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.

Gorden KB, Gorski KS, Gibson SJ, Kedl RM, Kieper WC, Qiu X, Tomai MA, Alkan SS, Vasilakos JP.

J Immunol. 2005 Feb 1;174(3):1259-68.

23.

Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.

Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, Barth RJ, Vasilakos JP, Noelle RJ, Kedl RM.

J Exp Med. 2004 Mar 15;199(6):775-84. Epub 2004 Mar 8.

24.
25.

Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.

Gibson SJ, Lindh JM, Riter TR, Gleason RM, Rogers LM, Fuller AE, Oesterich JL, Gorden KB, Qiu X, McKane SW, Noelle RJ, Miller RL, Kedl RM, Fitzgerald-Bocarsly P, Tomai MA, Vasilakos JP.

Cell Immunol. 2002 Jul-Aug;218(1-2):74-86.

PMID:
12470615
26.

Adjuvant activities of immune response modifier R-848: comparison with CpG ODN.

Vasilakos JP, Smith RM, Gibson SJ, Lindh JM, Pederson LK, Reiter MJ, Smith MH, Tomai MA.

Cell Immunol. 2000 Aug 25;204(1):64-74.

PMID:
11006019
27.

Dendritic cell maturation and subsequent enhanced T-cell stimulation induced with the novel synthetic immune response modifier R-848.

Ahonen CL, Gibson SJ, Smith RM, Pederson LK, Lindh JM, Tomai MA, Vasilakos JP.

Cell Immunol. 1999 Oct 10;197(1):62-72.

PMID:
10555997
28.

Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R-848 and imiquimod.

Wagner TL, Ahonen CL, Couture AM, Gibson SJ, Miller RL, Smith RM, Reiter MJ, Vasilakos JP, Tomai MA.

Cell Immunol. 1999 Jan 10;191(1):10-9.

PMID:
9918682
29.

Contribution of the ICE family to neurodegeneration.

Shivers BD, Boxer PA, Keane KM, Kupina NC, Lynch T, Schielke GP, Vartanian MG, Vasilakos JP.

Ann N Y Acad Sci. 1998 May 1;840:59-64. Review.

30.

Inhibition of the interleukin-1 beta converting enzyme family rescues neurons from apoptotic death.

Lynch T, Vasilakos JP, Raser K, Keane KM, Shivers BD.

Mol Psychiatry. 1997 May;2(3):227-38.

PMID:
9152987
31.

Caspase-3/CPP32-like activity is not sufficient to mediate apoptosis in an IL-2 dependent T cell line.

Vasilakos JP, Lynch T, Ghayur T, Giegel DA, Santoro M, Shivers BD.

Apoptosis. 1997;2(3):289-303.

32.

IL-1 beta converting enzyme (ICE) is not required for apoptosis induced by lymphokine deprivation in an IL-2-dependent T cell line.

Vasilakos JP, Ghayur T, Carroll RT, Giegel DA, Saunders JM, Quintal L, Keane KM, Shivers BD.

J Immunol. 1995 Oct 1;155(7):3433-42.

PMID:
7561038
33.

Interleukin-1 beta dissociates beta-amyloid precursor protein and beta-amyloid peptide secretion.

Vasilakos JP, Carroll RT, Emmerling MR, Doyle PD, Davis RE, Kim KS, Shivers BD.

FEBS Lett. 1994 Nov 14;354(3):289-92.

34.
35.
36.

Supplemental Content

Loading ...
Support Center